Data as of Dec 17
| +0.50 / +0.97%|
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Its products address the unmet medical needs of patients for a broad spectrum of diseases, including hepatitis, muscle wasting, alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. The company operates its business through two segments: CyDex and Ligand. The CyDex segment engages in development and commercialization of drugs using Captisol technology by CyDex Pharmaceuticals, Inc. The Ligand segment engages in developing or acquiring royalty revenue generating assets. Ligand Pharmaceuticals was founded by Ronald M. Evans in 1987 and is headquartered in La Jolla, CA.
|John L. Higgins||President, Chief Executive Officer & Director|
|Matthew W. Foehr||Chief Operating Officer & Executive Vice President|
|Nishan M. de Silva||Chief Financial Officer & Vice President-Strategy|
|Charles S. Berkman||Secretary, Vice President & General Counsel|
|James D. Pipkin||Vice President-New Product Development|